Sugi Predict

Sugi Predict / Compounds / SCHEMBL1012559

SCHEMBL1012559

SCHEMBL1012559

O=C(OCCCCCI)c1ccccc1

nearest known ligand 0.79

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.79
▸ LMNA P02545 3/20 0.58
▸ MAPK1 P28482 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ SLC6A2 P23975 1/20 0.50
▸ SLC6A3 Q01959 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2649692 0.93 TDP1 (0.78) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL17466182 0.91 TDP1 (0.96) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL11896235 0.91 TDP1 (0.96) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL11896606 0.91 TDP1 (0.96) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL223238 0.91 TDP1 (0.96) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL2069111 0.91 TDP1 (0.96) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL225815 0.91 TDP1 (0.96) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL28455123 0.90 TDP1 (0.64) TDP1LMNAALDH1A1NPC1MAPT
Ammonia Solution, Strong SCHEMBL2530225 0.89 TDP1 (0.92) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL223441 0.89 TDP1 (1.00) TDP1LMNAMAPK1HIF1ASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200087338-A1 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS SPRING BANK PHARMACEUTICALS INC (US) 2020-03-19 — — US disclosed
EP-3553072-A1 COMPOSITIONS COMPRISING DINUCLEOTIDE PRODRUGS Spring Bank Pharmaceuticals, Inc. (US) 2019-10-16 — — EP disclosed
US-10376533-B2 Compositions and methods for treating viral infections SPRING BANK PHARMACEUTICALS, INC. (US) 2019-08-13 — — US disclosed
US-10344046-B2 Nucleotide and oligonucleotide prodrugs SPRING BANK PHARMACEUTICALS, INC. (US) 2019-07-09 — — US disclosed
EP-3090748-B1 COMPOSITIONS COMPRISING NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS SPRING BANK PHARMACEUTICALS INC (US) 2019-02-20 — — EP disclosed
US-20180273574-A1 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS SPRING BANK PHARMACEUTICALS, INC. 2018-09-27 — — US disclosed
CN-107753499-A For treating the Compounds and methods for of virus infection 春堤制药公司 2018-03-06 — — CN disclosed
CN-103816174-B For treating the Compounds and methods for of virus infection 春堤制药公司 2017-12-05 — — CN disclosed
US-20170304344-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS SPRING BANK PHARMACEUTICALS, INC. 2017-10-26 — — US disclosed
US-9539276-B2 Compositions and methods for treating viral infections SPRING BANK PHARMACEUTICALS, INC. (US) 2017-01-10 — — US disclosed
US-8076303-B2 Nucleotide and oligonucleotide prodrugs SPRING BANK PHARMACEUTICALS, INC. (US) 2011-12-13 — — US disclosed
US-20110207690-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS SPRING BANK PHARMACEUTICALS, INC. (US) 2011-08-25 — — US disclosed
CN-102123716-A Compounds and methods for treating viral infections SPRING BANK 2011-07-13 — — CN disclosed
EP-2271351-A2 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS SPRING BANK (US) 2011-01-12 — — EP disclosed
WO-2009146123-A2 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS SPRING BANK (US) 2009-12-03 — — WO disclosed
CN-101437397-A Nucleotide and oligonucleotide prodrugs SPRING BANK (US) 2009-05-20 — — CN disclosed
EP-1968612-A2 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS SPRING BANK (US) 2008-09-17 — — EP disclosed
WO-2007070598-A9 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS SPRING BANK (US) 2007-11-08 — — WO disclosed
US-20070149462-A1 Nucleotide and oligonucleotide prodrugs SPRING BANK PHARMACEUTICALS, INC. 2007-06-28 — — US disclosed
WO-2007070598-A2 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS SPRING BANK (US) 2007-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200087338-A1 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS TYMP, PNP, DUT TDP1 593/4885LMNA 1746/4885MAPK1 3112/4885
US-10376533-B2 Compositions and methods for treating viral infections SLC10A1, HAVCR2, CYP3A43 TDP1 2064/4885LMNA 2008/4885MAPK1 3157/4885
US-20110207690-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS SLC10A1, HAVCR2, CYP3A43 TDP1 2064/4885LMNA 2008/4885MAPK1 3157/4885
US-20070149462-A1 Nucleotide and oligonucleotide prodrugs TYMP, PNP, DUT TDP1 593/4885LMNA 1746/4885MAPK1 3112/4885
US-10344046-B2 Nucleotide and oligonucleotide prodrugs TYMP, PNP, DUT TDP1 593/4885LMNA 1746/4885MAPK1 3112/4885
US-20180273574-A1 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS TYMP, PNP, DUT TDP1 593/4885LMNA 1746/4885MAPK1 3112/4885
US-20170304344-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS SLC10A1, HAVCR2, CYP3A43 TDP1 2064/4885LMNA 2008/4885MAPK1 3157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.